WAC and ASP of Herceptin (trastuzumab) biosimilars in the US 2022

As of 2022, biosimilar Herzuma (trastuzumab-pkrb) launched at an average sales price of six percent less than Herceptin's ASP, while biosimilar Trazimera (trastuzumab-qyyp) launched at an average sales price of 19 percent less than Herceptin's. This statistic illustrates the wholesale acquisition cost and average sales price of Herceptin (trastuzumab) biosimilars in the United States.

截至2022年，生物类似药Herzuma（trastuzumab-pkrb）的上市平均销售价格比赫赛汀（Herceptin）的平均销售价格低六个百分点，而生物类似药Trazimera（trastuzumab-qyyp）的上市平均销售价格则比赫赛汀低十九个百分点。此统计数据展示了美国赫赛汀（trastuzumab）生物类似药的批发采购成本和平均销售价格。